Mostrar el registro sencillo del ítem

Artículo

dc.creatorBallesteros Sánchez, Antonioes
dc.creatorSánchez González, José Maríaes
dc.creatorTedesco, Giovanni Robertoes
dc.creatorRocha de Lossada, Carloses
dc.creatorMurano, G.es
dc.creatorSpinelli, Antonioes
dc.creatorMazzotta, Cosimoes
dc.creatorBorroni, Davidees
dc.date.accessioned2024-06-03T15:45:22Z
dc.date.available2024-06-03T15:45:22Z
dc.date.issued2024-03-12
dc.identifier.citationBallesteros Sánchez, A., Sánchez González, J.M., Tedesco, G.R., Rocha de Lossada, C., Murano, G., Spinelli, A.,...,Borroni, D. (2024). Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief. Journal of Clinical Medicine, 13 (6), 1618. https://doi.org/10.3390/jcm13061618.
dc.identifier.issn2077-0383es
dc.identifier.urihttps://hdl.handle.net/11441/159630
dc.description.abstractBackground: To evaluate the effects of 10% GlicoPro tear substitute therapy in patients with severe dry eye disease (DED). Methods: In this prospective longitudinal study, 30 individuals receiving 10% GlicoPro four times daily for DED were evaluated. The ocular surface disease index (OSDI) questionnaire, average non-invasive break-up time (A-NIBUT), non-anesthetic and anesthetic corneal esthesiometry (CE), ocular pain, and the presence of conjunctivochalasis (CCH) were used as clinical endpoints. Treatment compliance using dosing diaries and AEs was assessed. Results: A significant improvement was observed in the clinical endpoints: the ΔOSDI questionnaire was −39.27 ± 13.22 [−65 to −15] points, ΔA-NIBUT was 3.10 ± 1.31 [1 to 5] s, Δnon-anesthetic CE was 14 ± 6.35 [5 to 25] mm, and Δanesthetic CE was 13 ± 5.35 [5 to 20] mm (p < 0.001 for all comparisons). Ocular pain was reduced in 92.5% of the patients at the end of the follow-up. However, there was no change in the presence of CCH. In addition, all the patients were fully compliant with the dosing and no AEs related to the use of the 10% GlicoPro tear substitute were reported. Conclusions: The 10% GlicoPro tear substitute has the potential to achieve beneficial effects in ocular surface treatments.es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es
dc.relation.ispartofJournal of Clinical Medicine, 13 (6), 1618.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCorneal esthesiometryes
dc.subjectDry eye diseasees
dc.subjectHelix aspersaes
dc.subjectOcular paines
dc.subjectTear substitutees
dc.titleEvaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Reliefes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Física de la Materia Condensadaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Cirugíaes
dc.relation.publisherversionhttps://doi.org/10.3390/jcm13061618es
dc.identifier.doi10.3390/jcm13061618es
dc.journaltitleJournal of Clinical Medicinees
dc.publication.volumen13es
dc.publication.issue6es
dc.publication.initialPage1618es

FicherosTamañoFormatoVerDescripción
Evaluating GlicoPro Tear.pdf903.5KbIcon   [PDF] Ver/Abrir   Versión publicada

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional